Literature DB >> 12796394

Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer.

Wulf Sienel1, Sebastian Dango, Ute Woelfle, Alicia Morresi-Hauf, Christoph Wagener, Jens Brümmer, Wolf Mutschler, Bernward Passlick, Klaus Pantel.   

Abstract

PURPOSE: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has recently been implicated in cancer development and progression. This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC). EXPERIMENTAL
DESIGN: Primary tumors of 145 consecutive patients with completely resected NSCLC (pT(1-4) pN(0-2) M(0) R(0)) were stained immunohistochemically using the monoclonal anti-CEACAM-1 antibody 4D1/C2. The prognostic relevance of CEACAM-1 expression was evaluated by univariate Kaplan-Meier and multivariate Cox regression analysis. The median follow-up period was 72 months (range, 10-130 months).
RESULTS: Normal bronchiolar epithelium present in all sections exhibited no immunostaining. In contrast, 73 tumors (50.4%) showed between 1 and 66% CEACAM-1 positive tumor cells, and 72 tumors (49.6%) exhibited even a higher percentage of positive tumor cells. A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). Multivariate Cox regression analysis demonstrated that CEACAM-1 represents an independent prognosticator for cancer-related survival (P = 0.018; relative risk, 1.8; 95% confidence interval, 1.1-2.8). Subgroup analysis revealed that a high CEACAM-1 expression rate was of significant prognostic impact in pN(1)-pN(2) patients (n = 60; P = 0.024), pT(3)-pT(4) patients (n = 22; P = 0.009), and stage IIa-IIIa patients (n = 69; P = 0.012).
CONCLUSIONS: The absence of CEACAM-1 in normal lung tissue and its expression in tumor cells argues against a tumor-suppressive role of CEACAM-1 in NSCLC. The correlation between elevated CEACAM-1 expression and an unfavorable prognosis indicates rather that CEACAM-1 might promote lung cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796394

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma.

Authors:  Shigehisa Kiriyama; Shozo Yokoyama; Masaki Ueno; Shinya Hayami; Junji Ieda; Naoyuki Yamamoto; Shunsuke Yamaguchi; Yasuyuki Mitani; Yasushi Nakamura; Masaji Tani; Lopa Mishra; John E Shively; Hiroki Yamaue
Journal:  Ann Surg Oncol       Date:  2014-01-06       Impact factor: 5.344

2.  High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.

Authors:  Mehrdad Asghari Estiar; Rezvan Esmaeili; Ali-Akbar Zare; Leila Farahmand; Hassan Fazilaty; Ali Zekri; Narges Jafarbeik-Iravani; Keivan Majidzadeh-A
Journal:  Clin Exp Med       Date:  2016-12-01       Impact factor: 3.984

3.  CEACAM1 enhances invasion and migration of melanocytic and melanoma cells.

Authors:  Alireza Ebrahimnejad; Thomas Streichert; Peter Nollau; Andrea K Horst; Christoph Wagener; Ana-Maria Bamberger; Jens Brümmer
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

4.  CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection.

Authors:  Benibelks Albarran-Somoza; Ramon Franco-Topete; Vidal Delgado-Rizo; Felipe Cerda-Camacho; Lourdes Acosta-Jimenez; Miguel Lopez-Botet; Adrian Daneri-Navarro
Journal:  J Histochem Cytochem       Date:  2006-08-21       Impact factor: 2.479

5.  Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.

Authors:  Ruben Pio; David Blanco; Maria Jose Pajares; Elena Aibar; Olga Durany; Teresa Ezponda; Jackeline Agorreta; Javier Gomez-Roman; Miguel Angel Anton; Angel Rubio; Maria D Lozano; Jose M López-Picazo; Francesc Subirada; Tamara Maes; Luis M Montuenga
Journal:  BMC Genomics       Date:  2010-06-03       Impact factor: 3.969

6.  CEACAM1 is overexpressed in oral tumors and related to tumorigenesis.

Authors:  Fu-Fang Wang; Bing-Xin Guan; Jing-Yan Yang; Hai-Tao Wang; Cheng-Jun Zhou
Journal:  Med Mol Morphol       Date:  2016-07-27       Impact factor: 2.309

7.  Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue.

Authors:  Ning Wang; Qing-Jie Wang; Yuan-Yong Feng; Wei Shang; Min Cai
Journal:  Clin Oral Investig       Date:  2013-07-19       Impact factor: 3.573

8.  Correlation between immunohistochemical staining of CEACAM1 and clinicopathological findings in oral pre-neoplastic lesions and squamous cell carcinoma.

Authors:  Oriana Simonetti; Guendalina Lucarini; Corrado Rubini; Antonio Zizzi; Simone Domenico Aspriello; Roberto Di Primio; Anna Maria Offidani
Journal:  Med Mol Morphol       Date:  2017-09-08       Impact factor: 2.309

Review 9.  Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.

Authors:  Nikolas K Haass; Keiran S M Smalley
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells.

Authors:  Bernhard B Singer; Inka Scheffrahn; Robert Kammerer; Norbert Suttorp; Suleyman Ergun; Hortense Slevogt
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.